Clinical Trial Update: Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating Panzem NCD, alone and in combination with Sunitinib Malate, in patients with met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Panzem NCD
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED